Inventor · disambiguated record
Kun Ping Lu
Also filed as: LU KUN · LU KUN P · LU KUN PING
26 granted patents·29 pending applications·235 citations·filing 1995–2025
96Inventor score
Files withBETH ISRAEL DEACONESS MEDICAL CT INC15REGENERON PHARMA8BETH ISRAEL HOSPITAL7SALK INST FOR BIOLOGICAL STUDI7LU KUN PING6
Top patents by PatentIndex Score
55 records- 0188US8771693B2Methods and compositions for the generation and use of conformation-specific antibodiesLU KUN PING·Filed 2010·Granted Jul 8, 2014·10 cites·20 claims
- 0288US7148003B2NIMA interacting proteinsSALK INST FOR BIOLOGICAL STUDI·Filed 2003·Granted Dec 12, 2006·12 cites·3 claims
- 0388US7125955B2NIMA interacting proteinsSALK INST FOR BIOLOGICAL STUDI·Filed 2003·Granted Oct 24, 2006·11 cites·4 claims
- 0487US8258099B2Pin1-modulating compounds and methods of use thereofLU KUN PING·Filed 2005·Granted Sep 4, 2012·12 cites·28 claims
- 0586US8129131B2Pin1 as a marker for abnormal cell growthLU KUN PING·Filed 2008·Granted Mar 6, 2012·14 cites·10 claims
- 0684US7164012B2NIMA interacting proteinsSALK INSTITUE FOR BIOLOG STUDI·Filed 2003·Granted Jan 16, 2007·11 cites·9 claims
- 0783US5952467ANIMA interacting proteinsSALK INST FOR BIOLOGICAL STUDI·Filed 1998·Granted Sep 14, 1999·34 cites·2 claims
- 0881US7125677B2NIMA interacting proteinsSALK INST FOR BIOLOGICAL STUDI·Filed 2003·Granted Oct 24, 2006·11 cites·7 claims
- 0981US6596848B1Antibodies to NIMA interacting proteinsSALK INST FOR BIOLOGICAL STUDI·Filed 1999·Granted Jul 22, 2003·30 cites·10 claims
- 1080US9688747B2Methods and compositions for the generation and use of conformation-specific antibodiesBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2014·Granted Jun 27, 2017·4 cites·14 claims
- 1179US9968579B2ATRA for modulating Pin1 activity and stabilityBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2015·Granted May 15, 2018·3 cites·19 claims
- 1278US6462173B1Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerasesMAX PLANCK GESELLSCHAFT·Filed 1997·Granted Oct 8, 2002·27 cites·19 claims
- 1378US5972697ANIMA interacting proteinsSALK INST FOR BIOLOGICAL STUDI·Filed 1995·Granted Oct 26, 1999·25 cites·5 claims
- 1474US10413548B2Methods and compositions for the inhibition of Pin1BETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2017·Granted Sep 17, 2019·1 cites·3 claims
- 1574US6495376B1Methods and compositions for regulating protein-protein interactionsBETH ISRAEL HOSPITAL·Filed 1999·Granted Dec 17, 2002·26 cites·7 claims
- 1672US10351914B2Biomarkers for Pin1-associated disordersBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2015·Granted Jul 16, 2019·1 cites·26 claims
- 1772US2023417701A1Ce-western applications for antibody developmentREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1871US2022317088A1Image capillary isoelectric focusing to analyze protein variants in a sample matrixREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1970US10265288B2Methods and compositions for the treatment of proliferative disordersBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2014·Granted Apr 23, 2019·1 cites·19 claims
- 2070US9730941B2Methods and compositions for the inhibition of Pin1BETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2013·Granted Aug 15, 2017·1 cites·3 claims
- 2170US2020291134A1Methods and compositions for the generation and use of conformation-specific antibodiesBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2019·Application pending·0 cites
- 2267US11782023B2Ce-western applications for antibody developmentREGENERON PHARMA·Filed 2019·Granted Oct 10, 2023·0 cites·18 claims
- 2367US2024385188A1Labeling and anti-drug antibody assays for aav vectorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2466US9439884B2Methods for the treatment of immune disordersLU KUN PING·Filed 2012·Granted Sep 13, 2016·1 cites·20 claims
- 2564US2007042467A1NIMA interacting proteinsSALK INST FOR BIOLOGICAL STUDI·Filed 2006·Application pending·0 cites
- 2663US9796784B2Methods and compositions for the generation and use of conformation-specific antibodiesBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2014·Granted Oct 24, 2017·0 cites·20 claims
- 2763US2025231141A1Vegf-trap protein variants and analysis thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2862US11129835B2Methods and compositions for the inhibition of PIN1BETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2019·Granted Sep 28, 2021·0 cites·4 claims
- 2960US2019056350A1Image capillary isoelectric focusing to analyze protein variants in a sample matrixREGENERON PHARMA·Filed 2018·Application pending·0 cites
- 3059US10485780B2Methods and compositions for the treatment of proliferative disordersLU KUN PING·Filed 2012·Granted Nov 26, 2019·0 cites·17 claims
- 3158US2018072814A1Methods and compositions for the generation and use of conformation-specific antibodiesBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2017·Application pending·0 cites
- 3258US2023296559A1Methods and systems for analyzing polypeptide variantsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3357US2023348578A1Conformation-specific antibodies that bind tau protein and uses thereofBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2021·Application pending·0 cites
- 3457US2025127783A1Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1), combinations and uses thereofDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 3556US2005282740A1Methods and compositions for regulating protein-protein interactionsLU KUN P·Filed 2004·Application pending·0 cites
- 3655US2025319053A1Inhibitors of the peptidyl-prolyl cis/trans isomerase (pin1), combinations and uses thereofDANA FARBER CANCER INST INC·Filed 2022·Application pending·0 cites
- 3755US2003109423A1Inhibitors of phosphoserine and phosphothreonine-proline-specific isomerasesMAX PLANCK GESELLSCHAFT·Filed 2002·Application pending·0 cites
- 3854US2022348645A1Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cellsBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2020·Application pending·0 cites
- 3953US2004142357A1Novel telomerase inhibitors and uses thereforBETH ISRAEL HOSPITAL·Filed 2003·Application pending·0 cites
- 4051US2003049672A1Methods and compositions for regulating protein-protein interactionsBETH ISRAEL HOSPITAL·Filed 2002·Application pending·0 cites
- 4150US2020393455A1Methods for identifying and quantitating host cell proteinREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4246US2005239095A1Use of Pin1 inhibitors for treatment of cancerBETH ISRAEL HOSPITAL·Filed 2004·Application pending·0 cites
- 4346US2004123334A1Methods of treating neurodegenerative diseasesBETH ISRAEL HOSPITAL·Filed 2004·Application pending·0 cites
- 4445US2005186643A1Pin1 as a marker for abnormal cell growthFiled 2003·Application pending·0 cites
- 4543US10980835B2Arsenic trioxide for treatment of PIN1-associated disordersBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2017·Granted Apr 20, 2021·0 cites·1 claims
- 4643US10487114B2Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereofLU KUN PING·Filed 2012·Granted Nov 26, 2019·0 cites·12 claims
- 4743US2021332024A1Modulators of pin1 activity and uses thereofYEDA RES & DEV·Filed 2021·Application pending·0 cites
- 4842US10548864B2Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditionsBETH ISRAEL DEACONESS MEDICAL CT INC·Filed 2016·Granted Feb 4, 2020·0 cites·17 claims
- 4942US2006074222A1Determination of a phosphorylation site in PPIase domain of Pin1 and uses thereforBETH ISRAEL HOSPITAL·Filed 2005·Application pending·0 cites
- 5042US2008058276A1Alzheimer's disease therapeutics based on pin-1 catalyzed conformational changes in phosphorylated amyloid precursor proteinCORNELL RES FOUNDATION INC·Filed 2007·Application pending·0 cites
Showing the top 50 of 55 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →